mRNA- and Adenovirus-Based Vaccines against SARS-CoV-2 in HIV-Positive People

被引：14

作者：

Garbuglia, Anna Rosa ^{[1
]}

Minosse, Claudia ^{[1
]}

Del Porto, Paola ^{[2
]}

机构：

[1] IRCCS, Lazzaro Spallanzani Natl Inst Infect Dis, Virol Lab, I-00149 Rome, Italy

[2] Sapienza Univ, Dept Biol & Biotechnol C Darwin, I-00100 Rome, Italy

来源：

VIRUSES-BASEL | 2022年 / 14卷 / 04期

关键词：

SARS-CoV-2; mRNA vaccine; adenoviral vaccine; HIV infection; immune response; CORONAVIRUS DISEASE 2019; REVERSE CAP ANALOGS; HUMAN-IMMUNODEFICIENCY-VIRUS; TRANSPLANT RECIPIENTS; ANTIBODY-RESPONSE; COVID-19; VACCINE; CATIONIC LIPIDS; TRANSLATION; SAFETY; IMMUNOGENICITY;

D O I：

10.3390/v14040748

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

About two years have passed since the identification of SARS-CoV-2 in China. The rapid spread of this virus all over the world and its high transmissibility and pathogenicity in humans have resulted in a global pandemic. The negative impact of COVID-19 on health, society and the economy at the global level has pushed researchers and pharmaceutical companies to develop effective vaccines to fight SARS-CoV-2. Thanks to this collaborative effort, the first COVID-19 vaccine was developed in less than a year. Since then, several COVID-19 vaccines have been validated for use by the World Health Organization. Among these, mRNA- (BNT162b2 and mRNA1273) and adenovirus-based (ChAdOx1) vaccines were developed through the use of novel technologies. While all three of these vaccines have shown effectiveness against the COVID-19 disease and their immunogenicity was characterized in clinical trials in the general population, data on their efficacy and immunogenicity in people living with HIV (PLWH) are limited. In this review, we provide a description of the characteristics of mRNA- and adenovirus-based vaccines and of the immune response elicited in the general population by vaccination. Then we describe the use of these vaccines and their efficacy and immunogenicity in people living with HIV and we conclude with a discussion regarding some open questions concerning the use of mRNA- and adenovirus-based COVID-19 vaccines in PLWH.

引用

页数：19

共 124 条

[41] Adenovirus-specific CD4+ T cell clones recognizing endogenous antigen inhibit viral replication in vitro through cognate interaction [J].

Heemskerk, Bianca ;

van Vreeswijk, Tamara ;

Veltrop-Duits, Louise A. ;

Sombroek, Claudia C. ;

Franken, Kees ;

Verhoosel, Renate M. ;

Hiemstra, Pieter S. ;

van Leeuwen, Daphne ;

Ressing, Maaike E. ;

Toes, Rene E. M. ;

van Tol, Maarten J. D. ;

Schilham, Marco W. .

JOURNAL OF IMMUNOLOGY, 2006, 177 (12) :8851-8859

[42] The pandemic pipeline [J].

Hodgson, John .

NATURE BIOTECHNOLOGY, 2020, 38 (05) :523-532

[43] SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor [J].

Hoffmann, Markus ;

Kleine-Weber, Hannah ;

Schroeder, Simon ;

Krueger, Nadine ;

Herrler, Tanja ;

Erichsen, Sandra ;

Schiergens, Tobias S. ;

Herrler, Georg ;

Wu, Nai-Huei ;

Nitsche, Andreas ;

Mueller, Marcel A. ;

Drosten, Christian ;

Poehlmann, Stefan .

CELL, 2020, 181 (02) :271-+

[44] Novel viral vectors in infectious diseases [J].

Humphreys, Ian R. ;

Sebastian, Sarah .

IMMUNOLOGY, 2018, 153 (01) :1-9

[45] Dynamic copy choice:: Steady state between murine leukemia virus polymerase and polymerase-dependent RNase H activity determines frequency of in vivo template switching [J].

Hwang, CK ;

Svarovskaia, ES ;

Pathak, VK .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (21) :12209-12214

[46] An mRNA Vaccine against SARS-CoV-2-Preliminary Report [J].

Jackson, L. A. ;

Anderson, E. J. ;

Rouphael, N. G. ;

Roberts, P. C. ;

Makhene, M. ;

Coler, R. N. ;

McCullough, M. P. ;

Chappell, J. D. ;

Denison, M. R. ;

Stevens, L. J. ;

Pruijssers, A. J. ;

McDermott, A. ;

Flach, B. ;

Doria-Rose, N. A. ;

Corbett, K. S. ;

Morabito, K. M. ;

O'Dell, S. ;

Schmidt, S. D. ;

Swanson, P. A. ;

Padilla, M. ;

Mascola, J. R. ;

Neuzil, K. M. ;

Bennett, H. ;

Sun, W. ;

Peters, E. ;

Makowski, M. ;

Albert, J. ;

Cross, K. ;

Buchanan, W. ;

Pikaart-Tautges, R. ;

Ledgerwood, J. E. ;

Graham, B. S. ;

Beigel, J. H. .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (20) :1920-1931

[47]

Jacobs G P, 2017, Public Health Action, V7, pS70, DOI 10.5588/pha.16.0101

[48] Humoral immune response following prime and boost BNT162b2 vaccination in people living with HIV on antiretroviral therapy [J].

Jedicke, Nils ;

Stankov, Metodi, V ;

Cossmann, Anne ;

Dopfer-Jablonka, Alexandra ;

Knuth, Christine ;

Ahrenstorf, Gerrit ;

Ramos, Gema Morillas ;

Behrens, Georg M. N. .

HIV MEDICINE, 2022, 23 (05) :558-563

[49] Novel "anti-reverse" cap analogs with superior translational properties [J].

Jemielity, J ;

Fowler, T ;

Zuberek, J ;

Stepinski, J ;

Lewdorowicz, M ;

Niedzwiecka, A ;

Stolarski, R ;

Darzynkiewicz, E ;

Rhoads, RE .

RNA, 2003, 9 (09) :1108-1122

[50]

Jobran Shaden, 2018, Lancet, V391 Suppl 2, pS43, DOI 10.1016/S0140-6736(18)30409-4

← 1 2 3 4 5 6 7 8 9 10 →